Press releases

Klaria accelerates its business development efforts

With Klaria’s Sumatriptan Alginate Film product in approval process Klaria is now accelerating its business development efforts and has engaged Ernst & Young AB Corporate Finance (EY) to identify potential strategic partnerships for its assets. In line with this, several options are being considered that could lead to different potential outcomes, with the objective to maximize shareholder value.

Klaria’s board of directors announces that CEO Jesper Wiklund leaves the company

The board of Klaria Pharma Holding AB (publ) announces that Jesper Wiklund is leaving the CEO position to focus on other activities based in Germany. Fredrik Hübinette, the company’s chairman of the board, will assume the position as acting CEO with immediate effect during a transition period.

Bulletin from the annual general meeting in Klaria Pharma Holding AB (publ)

Klaria Pharma Holding AB (publ) issues notice to attend the annual general meeting

The Swedish Financial Supervisory Authority initiates investigation of Klaria Pharma’s handling and disclosing of inside information

Klaria receives 2,6 MSEK payment from Imbrium Therapeutics in the Epinephrine Alginate Film R&D Collaboration

Klaria Pharmaceuticals announced today that it has received additional funding from its partner Imbrium Therapeutics to fund additional research in the Epinephrine Alginate Film collaboration.  The partners are collaborating on the research and development of Epinephrine Alginate Film for the treatment of serious allergic reactions, so called Anaphylactic Shock. 

Outcome in Klaria’s rights issue

Klaria Pharma Holding AB: Klaria publishes prospectus relating to the rights issue and gives update regarding the level of undertaking of the rights issue

Klaria Pharma Holding AB (”Klaria” or the “Company") today announces that the prospectus relating to the Company's rights issue (the "Rights Issue") has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”, sw. Finansinspektionen) (the "Prospectus"). The Company also announces that the Rights Issue of up to SEK 74.0 M before issuing costs has been secured up to 80 per cent by an increased top guarantee undertaking.

Bulletin from the extraordinary general meeting in Klaria Pharma Holding AB (publ)

At the extraordinary general meeting held in Klaria Pharma Holding AB (publ) today on 30 November 2022, it was resolved to approve the board of directors’ resolution on issuance of shares with preferential rights for the shareholders (in accordance with the proposal presented in the notice to attend the meeting kept available at the company’s website www.klaria.com).

Klaria submits Marketing Authorization Application for Sumatriptan Alginate Film in Europe

UPPSALA — November 29, 2022 — Klaria Pharma AB (publ) (Nasdaq Stockholm: KLAR) today announces that the Company has submitted a Marketing Authorization Application (MAA) for Sumatriptan Alginate Film for the treatment of Migraine in the European Union.  Pending positive validation, Sumatriptan Alginate Film will be subject to a regulatory assessment according to the standard timeline, which would result in approval in Q1, 2024.

Klaria Pharma Holding AB (publ) issues notice to attend extraordinary general meeting

The shareholders in Klaria Pharma Holding AB (publ), reg. no. 556959-2917, are hereby given notice to attend the extraordinary general meeting on 30 November 2022.

Klaria and PharmaMar initiate collaboration with a one-year study to develop a clinical development candidate of a PharmaMar compound formulated in Klaria’s Alginate Film technology

Klaria Pharma Holding AB (Nasdaq Stockholm: KLAR) announces that the company has signed an agreement with the Spanish biopharmaceutical company Pharma Mar (MSE:PHM), with the aim of performing a feasibility study for the purpose of developing an Alginate Film formulation of a PharmaMar compound. In the event of a positive outcome for this formulation development, the parties intend to negotiate a license agreement which will grant PharmaMar the global rights to the product.